Compositions and Methods for Treatment of Metabolic Disorders and Diseases
AssigneeNGM Biopharmaceuticals, Inc.
InventorsLei Ling, Darrin Anthony Lindhout
Life of this patent
Estimating the term…
Abstract
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and/or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Claims40
-5. (canceled)
A peptide sequence, comprising or consisting of
- a) a fibroblast growth factor 19 (FGF19) sequence variant having one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19;
- b) a portion of an FGF19 sequence fused to a portion of an FGF21 sequence, wherein the FGF19 and/or FGF21 sequence portion(s) have one or more amino acid substitutions, insertions or deletions compared to a reference or wild type FGF19 and/or FGF21;
- wherein the peptide sequence comprises at least one amino acid substitution to amino acid residues 125-129 of SEQ ID NO:99 [FGF19], EIRPD;
- at least one amino acid substitution to amino acid residues 126-128 of SEQ ID NO:99 [FGF19], IRP;
- or at least one amino acid substitution to amino acid residues 127-128 of SEQ ID NO:99 [FGF19]. RP.
(canceled)
(canceled)
-20. (canceled)
-29. (canceled)
-43. (canceled)
-49. (canceled)
-52. (canceled)
-56. (canceled)
-60. (canceled)
(canceled)
(canceled)
(canceled)
(canceled)
-79. (canceled)
Dependencies are inferred from the claim text.